Eli Lilly infectious disease acquisitions have officially signaled a new era for Eli Lilly and Company as they aggressively expand their footprint in the anti-infective [Read More…]
Gilead Sciences has finalized its $7.8 billion acquisition of Arcellx, Inc., positioning the company for the potential 2026 commercial launch of the BCMA-directed CAR T-cell therapy, anito-cel.
Eli Lilly and Company expands its oncology portfolio through the Lilly Ajax Therapeutics acquisition, targeting breakthroughs in myeloproliferative neoplasms with AJ1-11095.
Sun Pharmaceutical Industries has announced a definitive agreement to acquire Organon & Co. for $11.75 billion, marking a major expansion into women’s health and biosimilars.
Johnson & Johnson Atraverse Medical’s acquisition marks a significant milestone in the field of electrophysiology. Johnson & Johnson (NYSE: JNJ) announced a definitive agreement to [Read More…]
